COMP <GO>
VTRS vs ABBV // RSI-14 & 200D SMA MOMENTUM
Viatris Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: VTRS 2
— ABBV 10
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ABBV
LAST: $19.04 (-0.83%) • MKT CAP: $22.05B
rsi-technicals
64.1
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
rsi-technicals
72.8
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VTRS VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VTRS | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 35.20% | 70.20% | -35.00 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -8.10% | 29.00% | -37.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 8.78% | 3.47% | +5.31 | VTRS | /fcf-yield <GO> |
| Operating Margin | -18.70% | 24.60% | -43.30 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -14.60% | 6.90% | -21.50 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -3.00% | 8.60% | -11.60 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.81 | 5.33 | -4.52 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 7.40% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 64.1 | 72.8 | -8.64 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.15 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 113.1x | -80.10 | VTRS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $22.05B | $513.86B | -$491.81B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VTRS REV | ABBV REV | VTRS GROSS % | ABBV GROSS % | VTRS FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $14.25B | $61.16B | 35.2% | 70.2% | $1.94B | $17.82B |
| FY 2024 | $14.69B | $56.33B | 38.3% | 70.0% | $1.98B | $17.83B |
| FY 2023 | $15.39B | $54.32B | 44.0% | 44.0% | $2.21B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VTRS // BETA 1.15
ABBV // BETA 1.15